The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Activating alleles of JAK3 in acute megakaryoblastic leukemia
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
SWISS-MODEL: an automated protein homology-modeling server
Schwede, T. (2003) · Nucleic Acids Research · doi:10.1093/nar/gkg520 · Cited by 5,606
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
Baxter, E. J., Scott, L. M., Campbell, P. J., East, C., Fourouclas, N., Swanton, S., Vassiliou, G. S., Bench, A. J., Boyd, E. M., Curtin, N., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)71142-9 · Cited by 3,548
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
James, C., Ugo, V., Le Couédic, J.-P., Staerk, J., Delhommeau, F., Lacout, C., Garçon, L., Raslova, H., Berger, R., Bennaceur-Griscelli, A., et al. (2005) · Nature · doi:10.1038/nature03546 · Cited by 3,544
A Gain-of-Function Mutation of JAK2 in Myeloproliferative Disorders
Kralovics, R., Passamonti, F., Buser, A. S., Teo, S.-S., Tiedt, R., Passweg, J. R., Tichelli, A., Cazzola, M., & Skoda, R. C. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051113 · Cited by 3,470
Levine, R. L., Wadleigh, M., Cools, J., Ebert, B. L., Wernig, G., Huntly, B. J. P., Boggon, T. J., Wlodarska, I., Clark, J. J., Moore, S., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.03.023 · Cited by 2,993
Self-citationRappsilber, J., Ishihama, Y., & Mann, M. (2003) · Analytical Chemistry · doi:10.1021/ac026117i · Cited by 2,644
Peng, J., Elias, J. E., Thoreen, C. C., Licklider, L. J., & Gygi, S. P. (2003) · Journal of Proteome Research · doi:10.1021/pr025556v · Cited by 1,647
Stamos, J., Sliwkowski, M. X., & Eigenbrot, C. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m207135200 · Cited by 1,574
Tyrosine Kinases as Targets for Cancer Therapy
Krause, D. S., & Van Etten, R. A. (2005) · New England Journal of Medicine · doi:10.1056/nejmra044389 · Cited by 1,387
Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies
Yamamoto, Y. (2001) · Blood · doi:10.1182/blood.v97.8.2434 · Cited by 1,150
Immunoaffinity profiling of tyrosine phosphorylation in cancer cells
Rush, J., Moritz, A., Lee, K. A., Guo, A., Goss, V. L., Spek, E. J., Zhang, H., Zha, X.-M., Polakiewicz, R. D., & Comb, M. J. (2005) · Nature Biotechnology · doi:10.1038/nbt1046 · Cited by 1,124
Self-citationInterleukin-2 Receptor γ Chain: a Functional Component of the Interleukin-7 Receptor
Noguchi, M., Nakamura, Y., Russell, S. M., Ziegler, S. F., Tsang, M., Cao, X., & Leonard, W. J. (1993) · Science · doi:10.1126/science.8266077 · Cited by 1,109
The role of FLT3 in haematopoietic malignancies
Stirewalt, D. L., & Radich, J. P. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1169 · Cited by 865
Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders
Jones, A. V. (2005) · Blood · doi:10.1182/blood-2005-03-1320 · Cited by 843
Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome
Wechsler, J., Greene, M., McDevitt, M. A., Anastasi, J., Karp, J. E., Le Beau, M. M., & Crispino, J. D. (2002) · Nature Genetics · doi:10.1038/ng955 · Cited by 760
Self-citationInteraction of IL-2Rβ and γ c Chains with Jak1 and Jak3: Implications for XSCID and XCID
Russell, S. M., Johnston, J. A., Noguchi, M., Kawamura, M., Bacon, C. M., Friedmann, M., Berg, M., McVicar, D. W., Witthuhn, B. A., Silvennoinen, O., et al. (1994) · Science · doi:10.1126/science.7973658 · Cited by 655
Defective Lymphoid Development in Mice Lacking Jak3
Nosaka, T., van Deursen, J. M. A., Tripp, R. A., Thierfelder, W. E., Witthuhn, B. A., McMickle, A. P., Doherty, P. C., Grosveld, G. C., & Ihle, J. N. (1995) · Science · doi:10.1126/science.270.5237.800 · Cited by 637
Tyrosine kinase – Role and significance in Cancer
Paul, M. K., & Mukhopadhyay, A. K. (2004) · International Journal of Medical Sciences · doi:10.7150/ijms.1.101 · Cited by 624
Identification of an Acquired JAK2 Mutation in Polycythemia Vera
Zhao, R., Xing, S., Li, Z., Fu, X., Li, Q., Krantz, S. B., & Zhao, Z. J. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.c500138200 · Cited by 615
Witthuhn, B. A., Silvennoinen, O., Miura, O., Lai, K. S., Cwik, C., Liu, E. T., & Ihle, J. N. (1994) · Nature · doi:10.1038/370153a0 · Cited by 613
Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor
Changelian, P. S., Flanagan, M. E., Ball, D. J., Kent, C. R., Magnuson, K. S., Martin, W. H., Rizzuti, B. J., Sawyer, P. S., Perry, B. D., Brissette, W. H., et al. (2003) · Science · doi:10.1126/science.1087061 · Cited by 607
Phosphorylation and activation of the Jak-3 Janus kinase in response to interleukin-2
Johnston, J. A., Kawamura, M., Kirken, R. A., Chen, Y.-Q., Blake, T. B., Shibuya, K., Ortaldo, J. R., McVicar, D. W., & O'Shea, J. J. (1994) · Nature · doi:10.1038/370151a0 · Cited by 595
Functional Activation of Jak1 and Jak3 by Selective Association with IL-2 Receptor Subunits
Miyazaki, T., Kawahara, A., Fujii, H., Nakagawa, Y., Minami, Y., Liu, Z.-J., Oishi, I., Silvennoinen, O., Witthuhn, B. A., Ihle, J. N., et al. (1994) · Science · doi:10.1126/science.7973659 · Cited by 589
Constitutively activated Jak-STAT pathway in T cells transformed with HTLV-I
Migone, T.-S., Lin, J.-X., Cereseto, A., Mulloy, J. C., O'Shea, J. J., Franchini, G., & Leonard, W. J. (1995) · Science · doi:10.1126/science.7604283 · Cited by 557
Defects in B Lymphocyte Maturation and T Lymphocyte Activation in Mice Lacking Jak3
Thomis, D. C., Gurniak, C. B., Tivol, E., Sharpe, A. H., & Berg, L. J. (1995) · Science · doi:10.1126/science.270.5237.794 · Cited by 537
Wernig, G., Mercher, T., Okabe, R., Levine, R. L., Lee, B. H., & Gilliland, D. G. (2006) · Blood · doi:10.1182/blood-2005-12-4824 · Cited by 483
Self-citationSomatic Mutations of the Protein Kinase Gene Family in Human Lung Cancer
Davies, H., Hunter, C., Smith, R., Stephens, P., Greenman, C., Bignell, G., Teague, J., Butler, A., Edkins, S., Stevens, C., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1855 · Cited by 469
Yokota, S., Kiyoi, H., Nakao, M., Iwai, T., Misawa, S., Okuda, T., Sonoda, Y., Abe, T., Kahsima, K., Matsuo, Y., et al. (1997) · Leukemia · doi:10.1038/sj.leu.2400812 · Cited by 455
CELLS MEDIATING ALLOGRAFT REJECTION
HALL, B. M. (1991) · Transplantation · doi:10.1097/00007890-199106000-00001 · Cited by 319
Saharinen, P., & Silvennoinen, O. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m205156200 · Cited by 318
O'Farrell, A.-M., Foran, J. M., Fiedler, W., Serve, H. L., Paquette, R. L., Cooper, M. A., Yuen, H. A., Louie, S. G., Kim, H., Nicholas, S., et al. (2003) · PubMed · Cited by 310
Self-citationDevelopmental stage–selective effect of somatically mutated leukemogenic transcription factor GATA1
Li, Z., Godinho, F. J., Klusmann, J.-H., Garriga-Canut, M., Yu, C., & Orkin, S. H. (2005) · Nature Genetics · doi:10.1038/ng1566 · Cited by 305
A new modality for immunosuppression: targeting the JAK/STAT pathway
O'Shea, J. J., Pesu, M., Borie, D. C., & Changelian, P. S. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1441 · Cited by 303
Schwaller, J., Frantsve, J., Aster, J., Williams, I. R., Tomasson, M. H., Ross, T. S., Peeters, P., Van Rompaey, L., Van Etten, R. A., Ilaria, R., et al. (1998) · The EMBO Journal · doi:10.1093/emboj/17.18.5321 · Cited by 245
Self-citationMutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia
Goemans, B. F., Zwaan, C. M., Miller, M., Zimmermann, M., Harlow, A., Meshinchi, S., Loonen, A. H., Hählen, K., Reinhardt, D., Creutzig, U., et al. (2005) · Leukemia · doi:10.1038/sj.leu.2403870 · Cited by 243
Self-citationTse, K.-F., Mukherjee, G., & Small, D. (2000) · Leukemia · doi:10.1038/sj.leu.2401905 · Cited by 195
A Novel Mode of Gleevec Binding Is Revealed by the Structure of Spleen Tyrosine Kinase
Atwell, S., Adams, J. M., Badger, J., Buchanan, M. D., Feil, I. K., Froning, K. J., Gao, X., Hendle, J., Keegan, K., Leon, B. C., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m409792200 · Cited by 193
Mechanism-based design of a protein kinase inhibitor.
Hubbard, S. R., Cole, P. A., Parang, K., Till, J. H., Ablooglu, A. J., & Kohanski, R. A. (2001) · Nature Structural Biology · doi:10.1038/83028 · Cited by 192
Na Nakorn, T., Traver, D., Weissman, I. L., & Akashi, K. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15272 · Cited by 189
Lindauer, K., Loerting, T., Liedl, K. R., & Kroemer, R. T. (2001) · Protein Engineering, Design and Selection · doi:10.1093/protein/14.1.27 · Cited by 182
Crystal structure of the Jak3 kinase domain in complex with a staurosporine analog
Boggon, T. J., Li, Y., Manley, P. W., & Eck, M. J. (2005) · Blood · doi:10.1182/blood-2005-02-0707 · Cited by 170
Self-citationNa Nakorn, T., Traver, D., Weissman, I. L., & Akashi, K. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215272 · Cited by 167
JAK1 and Tyk2 Activation by the Homologous Polycythemia Vera JAK2 V617F Mutation
Staerk, J., Kallin, A., Demoulin, J.-B., Vainchenker, W., & Constantinescu, S. N. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.c500358200 · Cited by 163
Fujitani, Y., Hibi, M., Fukada, T., Takahashi-Tezuka, M., Yoshida, H., Yamaguchi, T., Sugiyama, K., Yamanaka, Y., Nakajima, K., & Hirano, T. (1997) · Oncogene · doi:10.1038/sj.onc.1200907 · Cited by 156
Regulation of constitutive STAT5 phosphorylation in acute myeloid leukemia blasts
Birkenkamp, K., Geugien, M., Lemmink, H. H., Kruijer, W., & Vellenga, E. (2001) · Leukemia · doi:10.1038/sj.leu.2402317 · Cited by 143
Chen, M., Cheng, A., Candotti, F., Zhou, Y.-J., Hymel, A., Fasth, A. L., Notarangelo, L. D., & O’Shea, J. J. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.3.947-956.2000 · Cited by 141
Jak3, severe combined immunodeficiency, and a new class of immunosuppressive drugs
Pesu, M., Candotti, F., Husa, M., Hofmann, S. R., Notarangelo, L. D., & O’Shea, J. J. (2005) · Immunological Reviews · doi:10.1111/j.0105-2896.2005.00220.x · Cited by 134
Transforming properties of chimeric TEL-JAK proteins in Ba/F3 cells
Penard‐Lacronique, V., Boureux, A., Monni, R., Dumon, S., Mauchauffé, M., Mayeux, P., Gouilleux, F., Berger, R., Gisselbrecht, S., Ghysdael, J., et al. (2000) · Blood · doi:10.1182/blood.v95.6.2076 · Cited by 130
Mutations in severe combined immune deficiency (SCID) due to JAK3 deficiency
Notarangelo, L. D., Mella, P., Jones, A., Basile, G. D. S., Savoldi, G., Cranston, T., Vihinen, M., & Schumacher, R. F. (2001) · Human Mutation · doi:10.1002/humu.1188 · Cited by 117
Xu, X., Kang, S. H., Heidenreich, O. T., Okerholm, M., O’Shea, J. J., & Nerenberg, M. I. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118193 · Cited by 112
Kawahara, A., Minami, Y., Miyazaki, T., Ihle, J. N., & Taniguchi, T. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.19.8724 · Cited by 103
Stepkowski, S. M., Erwin-Cohen, R. A., Behbod, F., Wang, M., Qu, X., Tejpal, N., Nagy, Z. S., Kahan, B. D., & Kirken, R. A. (2002) · Blood · doi:10.1182/blood.v99.2.680 · Cited by 96
Lai, K. S., Yan, J., Graham, D. K., Witthuhn, B. A., Ihle, J. N., & Liu, E. T. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.42.25028 · Cited by 75
Regulation of JAK3 expression and activation in human B cells and B cell malignancies
Tortolani, P. J., Lal, B. K., Riva, A., Johnston, J. A., Chen, Y. Q., Reaman, G. H., Beckwith, M., Longo, D., Ortaldo, J. R., Bhatia, K., et al. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.155.11.5220 · Cited by 74
JAK3 inhibition, a viable new modality of immunosuppression for solid organ transplants
Borie, D. C., O’Shea, J. J., & Changelian, P. S. (2004) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2004.09.007 · Cited by 72
Hayakawa, F., Towatari, M., Iida, H., Wakao, H., Kiyoi, H., Naoe, T., & Saito, H. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.00720.x · Cited by 71
Targeting Janus Kinase 3 in Mast Cells Prevents Immediate Hypersensitivity Reactions and Anaphylaxis
Malaviya, R., Zhu, D., Dıbırdık, İ., & Uckun, F. M. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.38.27028 · Cited by 68
The Three-dimensional Structure of the ZAP-70 Kinase Domain in Complex with Staurosporine
Jin, L., Pluskey, S., Petrella, E. C., Cantin, S. M., Gorga, J. C., Rynkiewicz, M. J., Pandey, P., Strickler, J. E., Babine, R. E., Weaver, D. T., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m407096200 · Cited by 66
Infectious Th1 and Th2 autoimmunity in diabetes‐prone mice
Tian, J., Olcott, A. P., Hanssen, L., Zekzer, D., Middleton, B., & Kaufman, D. L. (1998) · Immunological Reviews · doi:10.1111/j.1600-065x.1998.tb01214.x · Cited by 62
Requirement for Jak3 in Mature T Cells: Its Role in Regulation of T Cell Homeostasis
Sohn, S. J., Forbush, K. A., Nguyen, N., Witthuhn, B. A., Nosaka, T., Ihle, J. N., & Perlmutter, R. M. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.160.5.2130 · Cited by 39
RNAi-induced down-regulation of FLT3 expression in AML cell lines increases sensitivity to MLN518
Walters, D. K., Stoffregen, E. P., Heinrich, M. C., Deininger, M. W., & Druker, B. J. (2004) · Blood · doi:10.1182/blood-2004-07-2758 · Cited by 36
Self-citationFlores‐Morales, A., Pircher, T. J., Silvennoinen, O., Gustafsson, J.-Α., Sánchez-Gómez, M., Norstedt, G., Haldosén, L.-A., & Wood, T. J. J. (1998) · Molecular and Cellular Endocrinology · doi:10.1016/s0303-7207(98)00054-9 · Cited by 23
Cited by
Targeting the IL-6/JAK/STAT3 signalling axis in cancer
Johnson, D. E., O'Keefe, R. A., & Grandis, J. R. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.8 · Cited by 3,110
The JAK/STAT signaling pathway: from bench to clinic
Hu, X., li, J., Fu, M., Zhao, X., & Wang, W. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00791-1 · Cited by 2,633
Global Survey of Phosphotyrosine Signaling Identifies Oncogenic Kinases in Lung Cancer
Rikova, K., Guo, A., Zeng, Q., Possemato, A., Yu, J., Haack, H., Nardone, J., Lee, K., Reeves, C., Li, Y., et al. (2007) · Cell · doi:10.1016/j.cell.2007.11.025 · Cited by 2,317
Self-citationPatient-derived models of acquired resistance can identify effective drug combinations for cancer
Crystal, A. S., Shaw, A. T., Sequist, L. V., Friboulet, L., Niederst, M. J., Lockerman, E. L., Frias, R. L., Gainor, J. F., Amzallag, A., Greninger, P., et al. (2014) · Science · doi:10.1126/science.1254721 · Cited by 708
Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders
Levine, R. L., Pardanani, A., Tefferi, A., & Gilliland, D. G. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2210 · Cited by 588
Self-citation
Metadata
- Authors
- Walters, D. K., Mercher, T., Gu, T.-L., O'Hare, T., Tyner, J. W., Loriaux, M., Goss, V. L., Lee, K. A., Eide, C. A., Wong, M. J., Stoffregen, E. P., McGreevey, L., Nardone, J., Moore, S. A., Crispino, J., Boggon, T. J., Heinrich, M. C., Deininger, M. W., Polakiewicz, R. D., Gilliland, D. G., & Druker, B. J.
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2006-07
- Volume
- 10
- Issue
- 1
- Pages
- 65-75
- ISSN
- 1535-6108 (ISSN-L)
- OpenAlex
- W2119674879
- Cited by
- 317
- References
- 62
- FWCI
- 13.69
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.